Wurth Douglas Clark reported grant involving 100,000 derivative units of Bluejay Diagnostics, Inc. at $0.00 for $0 on Aug 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Aug 18, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
100,000Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
100,000Direct
Trade date
Aug 17, 2026Grant
Filed
Aug 18, 2026, 4:16 PM ET1-day reporting delay
Accession
0001123292-26-001126Code A · Transaction 2219
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

BJDX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BJDX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +49%1w ago +1%1d ago +8.2%
Returns since7d −2.1%30d −16%90d180d1y

Footnotes in full

F1: Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.